|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________
Form
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
or
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________ to _____________________
Commission File Number:
____________
(Exact name of the registrant as specified in its charter)
|
|
(State or other jurisdiction of | (I.R.S. Employer |
(
(Address and telephone number of the registrant’s principal executive offices)
|
|
|
Title of each class | Trading Symbol(s) | Name of exchange on which registered |
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit such files).
Yes No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
Large accelerated filer | o | Accelerated filer | o | x | Smaller reporting company | ||
|
|
|
|
|
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No
At August 8, 2022, the registrant had
|
|
AquaBounty Technologies, Inc. | ||
FORM 10-Q | ||
For the Quarterly Period Ended June 30, 2022 | ||
| ||
TABLE OF CONTENTS | ||
| ||
| ||
Page | ||
1 | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | 12 | |
18 | ||
18 | ||
| ||
19 | ||
19 | ||
20 | ||
20 | ||
20 | ||
20 | ||
21 | ||
21 |
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q, particularly the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward looking statements. All statements other than present and historical facts and conditions contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial positions, business strategy, plans, and our objectives for future operations, are forward-looking statements. When used in this Quarterly Report on Form 10-Q, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. These forward-looking statements include statements that are not historical facts, including statements regarding management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; the nature of and progress toward our commercialization plan; the future introduction of our products to consumers; the countries in which we may obtain regulatory approval and the progress toward such approvals; the volume of eggs or fish we may be able to produce; the timeline for our production of saleable fish; the expected advantages of land-based systems over sea cage production; the validity and impact of legal actions; the completion of renovations at our farms; and the establishment of a larger-scale grow-out facility.
We have based these forward-looking statements on our current expectations, assumptions, estimates, and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties, and other factors, many of which are outside of our control, which could cause our actual results, performance, or achievements to differ materially from any results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
the anticipated benefits and characteristics of AquaBounty’s genetically engineered AquAdvantage salmon (“GE Atlantic salmon”) product;
the implementation and likelihood of achieving the business plan, future revenue, and operating results;
our plans for (including without limitation, projected costs, locations and third-party involvement) and the timing of the development of new farms and the output of those farms (including our Pioneer, Ohio farm);
developments concerning our research projects;
our expectations regarding our ability to successfully enter new markets or develop additional products;
our competitive position and developments and projections relating to our competitors and our industry;
expectations regarding anticipated operating results;
our cash position, our ability to raise additional capital to finance our activities and the terms of such financing, including interest rates on debt;
the impact of the evolving COVID-19 pandemic (the “COVID-19 pandemic”) on our business, operations and financial results, any of which could be significantly impaired by the COVID-19 pandemic;
our ability to protect our intellectual property and other proprietary rights and technologies;
the impact of and our ability to adapt to changes in laws or regulations and policies;
the ability to secure any necessary regulatory approvals to commercialize any products;
the rate and degree of market acceptance of any products developed through the application of bioengineering, including genetically engineered fish;
our ability to retain and recruit key personnel;
the success of any of our future acquisitions or investments;
our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”);
our estimates regarding expenses, inflation, future revenue, capital requirements, and needs for additional financing; and
other risks and uncertainties referenced under “Risk Factors” below and in any documents incorporated by reference herein.
We caution you that the foregoing list may not contain all of the risks to which the forward-looking statements made in this Quarterly Report on Form 10-Q are subject. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included, particularly in the section titled “Risk Factors,” that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments that we may make.
Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this Quarterly Report on Form 10-Q. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments unless required by federal securities law. New risks emerge from time to time, and it is not possible for us to predict all such risks.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
AquaBounty Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
|
|
|
|
|
|
|
| June 30, |
|
| December 31, |
| 2022 |
| 2021 | ||
Assets |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents | $ | |
| $ | |
Marketable securities |
| |
|
| |
Inventory |
| |
|
| |
Prepaid expenses and other current assets |
| |
|
| |
Total current assets |
| |
|
| |
|
|
|
|
|
|
Property, plant and equipment, net |
| |
|
| |
Right of use assets, net |
| |
|
| |
Intangible assets, net |
| |
|
| |
Restricted cash |
| |
|
| |
Other assets |
| |
|
| |
Total assets | $ | |
| $ | |
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable and accrued liabilities | $ | |
| $ | |
Accrued employee compensation |
| |
|
| |
Current debt |
| |
|
| |
Other current liabilities |
| |
|
| |
Total current liabilities |
| |
|
| |
|
|
|
|
|
|
Long-term lease obligations |
| |
|
| |
Long-term debt, net |
| |
|
| |
Total liabilities |
| |
|
| |
|
|
|
|
|
|
Commitments and contingencies |
|
|
| ||
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
Common stock, $ |
|
|
|
|
|
June 30, 2022 and December 31, 2021, respectively; |
|
|
|
|
|
outstanding at June 30, 2022 and December 31, 2021, respectively |
| |
|
| |
Additional paid-in capital |
| |
|
| |
Accumulated other comprehensive loss |
| ( |
|
| ( |
Accumulated deficit |
| ( |
|
| ( |
Total stockholders' equity |
| |
|
| |
|
|
|
|
|
|
Total liabilities and stockholders' equity | $ | |
| $ | |
See accompanying notes to these condensed interim consolidated financial statements.
AquaBounty Technologies, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
| Six Months Ended | ||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | ||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
Product revenues | $ | |
| $ | |
| $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
Product costs |
| |
|
| |
|
| |
|
| |
Sales and marketing |
| |
|
| |
|
| |
|
| |
Research and development |
| |
|
| |
|
| |
|
| |
General and administrative |
| |
|
| |
|
| |
|
| |
Total costs and expenses |
| |
|
| |
|
| |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss |
| ( |
|
| ( |
|
| ( |
|
| ( |
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
| ( |
|
| ( |
|
| ( |
|
| ( |
Other income, net |
| |
|
| |
|
| |
|
| |
Total other income (expense) |
| |
|
| ( |
|
| |
|
| ( |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss | $ | ( |
| $ | ( |
| $ | ( |
| $ | ( |
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) income: |
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation (loss) gain |
| ( |
|
| |
|
| ( |
|
| |
Unrealized gain on marketable securities |
| |
|
| |
|
| |
|
| |
Total other comprehensive (loss) income |
| ( |
|
| |
|
| ( |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss | $ | ( |
| $ | ( |
| $ | ( |
| $ | ( |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share | $ | ( |
| $ | ( |
| $ | ( |
| $ | ( |
Weighted average number of Common Shares - |
|
|
|
|
|
|
|
|
|
|
|
basic and diluted |
| |
|
| |
|
| |
|
| |
See accompanying notes to these condensed interim consolidated financial statements.
AquaBounty Technologies, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued and outstanding |
| Par value |
| Additional paid-in capital |
| Accumulated other comprehensive loss |
| Accumulated deficit |
| Total | ||||||
Balance at December 31, 2020 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
| ( |
|
| ( |
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
Cashless exercise of options for common stock |
| |
|
| |
|
| ( |
|
|
|
|
|
|
|
| — |
Issuance of common stock, net of expenses |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Exercise of warrants for common stock |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Share based compensation |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Balance at March 31, 2021 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
| ( |
|
| ( |
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
Exercise of warrants for common stock |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Share based compensation |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Balance at June 30, 2021 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued and outstanding |
| Par value |
| Additional paid-in capital |
| Accumulated other comprehensive loss |
| Accumulated deficit |
| Total | ||||||
Balance at December 31, 2021 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
| ( |
|
| ( |
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
| ( |
|
|
|
|
| ( |
Share based compensation |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Balance at March 31, 2022 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
| ( |
|
| ( |
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
| ( |
|
|
|
|
| ( |
Exercise of options for common stock |
| |
|
| |
|
| |
|
|
|
|
|
|
|
| |
Share based compensation |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Balance at June 30, 2022 |
| |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | |
See accompanying notes to these condensed interim consolidated financial statements.
AquaBounty Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
|
|
|
|
|
|
| Six Months Ended June 30, | ||||
| 2022 |
| 2021 | ||
Operating activities |
|
|
|
|
|
Net loss | $ | ( |
| $ | ( |
Adjustment to reconcile net loss to net cash used in |
|
|
|
|
|
operating activities: |
|
|
|
|
|
Depreciation and amortization |
| |
|
| |
Share-based compensation |
| |
|
| |
Other non-cash charge |
| |
|
| |
Changes in operating assets and liabilities: |
|
|
|
|
|
Inventory |
| ( |
|
| ( |
Prepaid expenses and other assets |
| ( |
|
| ( |
Accounts payable and accrued liabilities |
| |
|
| ( |
Accrued employee compensation |
| ( |
|
| ( |
Net cash used in operating activities |
| ( |
|
| ( |
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
Purchases and deposits on property, plant and equipment |
| ( |
|
| ( |
Maturities of marketable securities |
| |
|
| |
Purchases of marketable securities |
| ( |
|
|